---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003764"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-06T23:57:58.435457+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Praxis raises ~$161.7M in stock/warrant offering; funds operations into 2026

## Summary
- Public offering of 3,168,275 shares of common at $35.50 and pre-funded warrants for 1,056,725 shares at $35.4999.
- Underwriters exercised option to purchase an additional 633,750 shares; total net proceeds ~$161.7M.
- Proceeds to fund Phase 3 studies for ulixacaltamide and clinical development of PRAX-628, PRAX-562, PRAX-222.
- Company believes net proceeds plus existing cash will fund operating expenses and capex into 2026.
- Closing expected January 16, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001104659-24-003764
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000110465924003764/0001104659-24-003764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000110465924003764/tm243213d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003764
- JSON: https://secwatch.observer/filing/0001104659-24-003764.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.